Loading stock data…
Nektar Therapeutics (NKTR)
$75.44+1.25 (+1.68%)
Market ClosedLast close Sep 8
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Nektar Therapeutics in the Healthcare sector is trading at $75.44 with a market capitalization of $2.0B. Wall Street consensus targets $144.40 (10 analysts), implying a +91.4% move over the next 12 months. The stock is currently 31% below its 52-week high of $109.00, remaining 16.1% above its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 85/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +91.4% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $10.86M↓ | $21.81M↑ | $11.79M↑ | $11.18M↑ | $10.46M |
| Gross Profit | — | $21.81M↑ | $11.79M↑ | $11.18M↑ | $10.46M |
| Operating Income | -$38.26M↓ | -$19.09M↑ | -$31.53M↑ | -$35.78M↑ | -$44.37M |
| Net Income | -$44.90M↓ | -$36.08M↓ | -$35.52M↑ | -$41.59M↑ | -$50.88M |
Peer Comparison
JNJUNHPFE
Fundamentals
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. It develops rezpegaldesleukin, which is in Phase 2b to treat underlying immune s...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$2.03B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-27.44%
Volume
Today's trading volume
861,941
Recent News
Nektar’s (NKTR) Billion-Dollar Balance Sheet Faces A Multi-Year Test
On August 13, Nektar Therapeutics (NASDAQ:NKTR) held its second-quarter earnings call and laid out where its lead drug candidate stands after years of development. Rezpegaldesleukin, known as rezpeg, is now enrolling patients in Phase 3 trials for two separate autoimmune conditions, atopic dermatitis and alopecia areata. Management framed the quarter around two numbers that matter […]
Nektar (NKTR) Q2 2026 Earnings Call Transcript
Phase 3 trials for rezpegaldesleukin advance in atopic dermatitis and alopecia areata.
Nektar Therapeutics (NKTR) Could Be 52% Undervalued After Q2 Earnings Surprise
Nektar Therapeutics (NKTR) shares are in focus after the company reported second quarter 2026 results, with revenue of US$10.13 million and a net loss of US$40.62 million, alongside an earnings surprise relative to analyst expectations. See our latest analysis for Nektar Therapeutics. Nektar Therapeutics shares have eased in the very short term, with a 1-day share price return of 3.82% and a 7-day share price return of 4.52%. However, the stock still shows strong momentum with a year to date...
Nektar Therapeutics (NKTR) Stock Looks Stretched Despite New Phase 3 Trial Launch
Nektar Therapeutics stock has delivered a very large gain over the past three years, yet the company now screens as expensive on broad valuation checks. After such a strong run, investors are facing a disconnect between past returns and what the current pricing suggests about future reward for risk. Nektar Therapeutics has returned almost 7x over the past three years, which raises the bar for any further upside from today's price. The launch of late stage trials for rezpegaldesleukin can...
Retail Sales Weaken in July
Retail Sales Weaken in July